TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28031860

Group type: EXPERIMENTAL
Intervention: Multi-factorial lifestyle intervention group (IG) - structured, individualized endurance training of ≥18 MET*h/week and personal nutritional counseling based on the Mediterranean diet.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG) - usual care, which includes one general counseling on healthy nutrition and benefits of regular physical activity.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multi-factorial lifestyle intervention group (IG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 60
Study: 28032129

Group type: EXPERIMENTAL
Intervention: Oral crizotinib at dose levels of 100, 130, 165, 215, 280 and 365 mg/m
Number of subjects: 64
Study: 28032216

Group type: EXPERIMENTAL
Intervention: Aprepitant 125/80/80 mg on a Monday, Wednesday, Friday schedule and oral ondansetron 8 mg po q12 h
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Aprepitant and ondansetron
Number of subjects: 55
Study: 28032323

Group type: EXPERIMENTAL
Intervention: Migraine presence with Major Depressive Disorder (MDD)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Migraine presence with Generalized Anxiety Disorder (GAD)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Participants without migraine
Number of subjects: 227
Study: 28033414

Group type: EXPERIMENTAL
Intervention: Multimorbidity Pattern A (mainly mental illness and bone impairments)
Number of subjects: 5647

Group type: EXPERIMENTAL
Intervention: Multimorbidity Pattern B (mainly cardiovascular and metabolic disorders)
Number of subjects: 5647
Study: 28034899

Group type: COMPARATOR
Intervention: European Society of Cardiology pathway
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: High-STEACS pathway
Number of subjects: 1218
Study: 28034990

Group type: EXPERIMENTAL
Intervention: Alisertib administered for 7 days after conventional induction with cytarabine and idarubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional induction with cytarabine and idarubicin
Number of subjects: 0
Study: 28034993

Group type: EXPERIMENTAL
Intervention: Lenalidomide combined with intensive chemotherapy (daunorubicin 45 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive chemotherapy (daunorubicin 45 mg/m2)
Number of subjects: 0
Study: 28035649

Group type: EXPERIMENTAL
Intervention: Targeted educational intervention (modified pamphlet with skin of color section, nomenclature 'melanoma skin cancer', and image of skin self-examination)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional pamphlet on the 'ABCDEs' of melanoma
Number of subjects: 100
Study: 28036330

Group type: EXPERIMENTAL
Intervention: Automated measurement methodology for J-Tpeakc and Tpeak-Tend intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Semi-automated measurements
Number of subjects: 0
Study: 28038669

Group type: EXPERIMENTAL
Intervention: New patient experience tool (25 item scale)
Number of subjects: 0
Study: 28039062

Group type: EXPERIMENTAL
Intervention: Syndromic SLE (n=10)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Familial SLE (n=12)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Other forms of early-onset SLE (n=42)
Number of subjects: 64
Study: 28039068

Group type: EXPERIMENTAL
Intervention: Endurance-plus-strengthening PA intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 400
Study: 28039079

Group type: EXPERIMENTAL
Intervention: Post-transplant cyclophosphamide 50 mg/kg (days +3 and +4) and tacrolimus/mycophenolate mofetil (T/MMF) (day +5 forward)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Post-transplant cyclophosphamide + T/MMF combination
Number of subjects: 35
Study: 28039155

Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus abiraterone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus abiraterone plus prednisone (5 mg twice daily)
Number of subjects: 37
Study: 28039229

Group type: EXPERIMENTAL
Intervention: Exercise echocardiography (E/e' ratio)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Resting echocardiography (E/e' ratio)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B type natriuretic peptide levels
Number of subjects: 74
Study: 28039242

Group type: EXPERIMENTAL
Intervention: Non-invasive assessment using CNAP™ technology measuring pulse pressure variation (PPV) during surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive leg-raising manoeuvre
Number of subjects: 0
Study: 28039250

Group type: EXPERIMENTAL
Intervention: T-view scoring system
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-view scoring system
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paired T and L-view scores
Number of subjects: 20
Study: 28039295

Group type: EXPERIMENTAL
Intervention: 3rd-generation CAR-T cells (1 million CAR-T cells per kg administered intravenously)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3rd-generation CAR-T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg intravenously every 6 hours) or IgG
Number of subjects: 0
Study: 28039367

Group type: EXPERIMENTAL
Intervention: ABT-414 (0.5-3.2 mg/kg every 2 weeks by intravenous infusion) plus radiation and temozolomide
Number of subjects: 45
Study: 28039616

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: N-Acetylcysteine
Number of subjects: 0
Study: 28040280

Group type: EXPERIMENTAL
Intervention: Pacemaker rhythm
Number of subjects: 300

Group type: COMPARATOR
Intervention: IVC
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Pacemaker rhythm (after propensity matching)
Number of subjects: 300

Group type: COMPARATOR
Intervention: IVC (after propensity matching)
Number of subjects: 300
Study: 28040318

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR)
Number of subjects: 30
Study: 28040992

Group type: EXPERIMENTAL
Intervention: Plasma TWEAK levels
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Mayo scores, MES-UC, SES-CD, CRP, fecal calprotectin
Number of subjects: 139

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 139
Study: 28041583

Group type: EXPERIMENTAL
Intervention: Ofatumumab plus miniCHOP regimen (1000 mg total dose of intravenous ofatumumab, 25 mg/m2 of cyclophosphamide, doxorubicin, vincristine, and prednisone) with pre-phase treatment (oral vincristine 1 mg total dose 1 week before cycle 1 and oral prednisone 60 mg total dose for 4 days before cycle 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pre-phase treatment (oral vincristine and oral prednisone)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 120
Study: 28042454

Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 18
Study: 28043455

Group type: EXPERIMENTAL
Intervention: 20-point score derived from 6 variables (birth weight, clinical syndrome or abnormal karyotype, surgeon Norwood volume or year, anatomic subtype, ascending aorta size, obstructed pulmonary venous return)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Validation cohort
Number of subjects: 549
Study: 28043488

Group type: EXPERIMENTAL
Intervention: Nyaditum resae (NR) - daily administration of 10 doses
Number of subjects: 0
Study: 28043939

Group type: EXPERIMENTAL
Intervention: Root tear
Number of subjects: 227

Group type: COMPARATOR
Intervention: No root tear
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Meniscal morphology (other types of tears)
Number of subjects: 227
Study: 28044005

Group type: EXPERIMENTAL
Intervention: Jacobian determinant
Number of subjects: 490
Study: 28044059

Group type: EXPERIMENTAL
Intervention: Hormone treatment (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Untreated LCLs from women with PMDD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Progesterone (in controls only)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estradiol (in PMDD LCLs)
Number of subjects: 0
Study: 28044265

Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 mg twice daily for 15 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 50
Study: 28045622

Group type: EXPERIMENTAL
Intervention: End-of-induction (EOI) minimal residual disease (MRD) assessment
Number of subjects: 3113

Group type: EXPERIMENTAL
Intervention: Low EOI MRD level (< 0.01%)
Number of subjects: 3113

Group type: EXPERIMENTAL
Intervention: High MRD (≥ 5%) among patients with morphologic remission
Number of subjects: 3113

Group type: EXPERIMENTAL
Intervention: Redefining induction failure to include morphologic induction failure and/or MRD ≥ 5%
Number of subjects: 3113

Group type: EXPERIMENTAL
Intervention: Induction failure (morphologic or MRD ≥ 5%)
Number of subjects: 3113
Study: 28045712

Group type: EXPERIMENTAL
Intervention: Option B+ (lifelong antiretroviral therapy)
Number of subjects: 24
Study: 28045923

Group type: EXPERIMENTAL
Intervention: Bevacizumab in addition to chemotherapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Chemotherapy alone (control)
Number of subjects: 63
Study: 28045969

Group type: EXPERIMENTAL
Intervention: Blue-light filtering spectacle lenses (BF: blue-filtering anti-reflection coating; BT: brown-tinted)
Number of subjects: 80
Study: 28049004

Group type: EXPERIMENTAL
Intervention: Near-Infrared Spectroscopy (NIRS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transcutaneous Oxygen Tension (TcPO2)
Number of subjects: 30
Study: 28049084

Group type: EXPERIMENTAL
Intervention: Real rTMS over the left DLPFC
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 22
Study: 28049461

Group type: EXPERIMENTAL
Intervention: Voluntary Admission (VA)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Compulsory Admission (CA)
Number of subjects: 202
Study: 28049470

Group type: EXPERIMENTAL
Intervention: Quality indicators for mental health care based on referral information
Number of subjects: 0
Study: 28049490

Group type: EXPERIMENTAL
Intervention: Balixafortide (POL6326) at doses of 500-2500 µg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 0
Study: 28049639

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study: 28049662

Group type: EXPERIMENTAL
Intervention: Weight-reduction program
Number of subjects: 27
Study: 28050885

Group type: EXPERIMENTAL
Intervention: pl-VEGF165 gene therapy (2 intramuscular injections for a total dose of 2.4 mg)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conservative therapy without prostaglandins and prostacyclins (Control group)
Number of subjects: 210
Study: 28050899

Group type: EXPERIMENTAL
Intervention: bioactive adrenomedullin (bio-ADM)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: lactate
Number of subjects: 178
Study: 28051798

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) monotherapy
Number of subjects: 40
Study: 28052755

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) patients
Number of subjects: 24658

Group type: COMPARATOR
Intervention: Patients without atrial fibrillation (AF)
Number of subjects: 24658
Study: 28052855

Group type: EXPERIMENTAL
Intervention: SYN-004 (ribaxamase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no ribaxamase)
Number of subjects: 0
Study: 28052860

Group type: EXPERIMENTAL
Intervention: PsA patients
Number of subjects: 90
Study: 28052888

Group type: EXPERIMENTAL
Intervention: HIV+ women receiving ART
Number of subjects: 246

Group type: COMPARATOR
Intervention: HIV-negative women
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: HIV status
Number of subjects: 246
Study: 28052957

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28053173

Group type: EXPERIMENTAL
Intervention: Indicator amino acid oxidation (IAAO) technique with l-[1-13C]Leucine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Current protein recommendations
Number of subjects: 4
Study: 28053674

Group type: EXPERIMENTAL
Intervention: Eccentric Training (EC)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Eccentric Training + Dietary Supplement (MCVC)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Passive Stretching + Dietary Supplement (MCVC)
Number of subjects: 59
Study: 28053784

Group type: EXPERIMENTAL
Intervention: SMS Text Messages for Prevention of Mother-to-Child Transmission of HIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 0
Study: 28053823

Group type: EXPERIMENTAL
Intervention: Mild-Caloric Restriction (MCD) with approximately 100 kcal/day deficit
Number of subjects: 0
Study: 28053879

Group type: EXPERIMENTAL
Intervention: Lysozyme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CXCL12
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (serum-free media post-wounding)
Number of subjects: 0
Study: 28053986

Group type: EXPERIMENTAL
Intervention: Preoperative chemical vestibular ablation with 1.0 mL of 40 mg/mL nonbuffered gentamicin in three intratympanic installations over 2 days, 2 months preoperatively
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group with home vestibular training only, 2 months preoperatively
Number of subjects: 20
Study: 28054442

Group type: EXPERIMENTAL
Intervention: Alloreactive NK cells from haploidentical donors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Size of the alloreactive NK cell population
Number of subjects: 0
Study: 28055031

Group type: EXPERIMENTAL
Intervention: Customized mobile application (App)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Paper instructions (Control)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sodium picosulfate/magnesium citrate (SPS)
Number of subjects: 160
Study: 28056030

Group type: EXPERIMENTAL
Intervention: Simeprevir plus Peginterferon/Ribavirin (PR) for 12 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Simeprevir plus Peginterferon/Ribavirin (PR) for 24 weeks
Number of subjects: 67
Study: 28056805

Group type: EXPERIMENTAL
Intervention: Endurance training (150min/week moderate or 75min/week vigorous exercise)
Number of subjects: 109
Study: 28056812

Group type: EXPERIMENTAL
Intervention: Anorexia Nervosa (AN)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal Weight Controls (HC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Obesity (OB)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Longitudinal follow-up after weight rehabilitation in AN
Number of subjects: 24
Study: 28056937

Group type: EXPERIMENTAL
Intervention: Body morphotype and composition measured using bioelectrical impedance analysis
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Presence of cavity on chest computed tomography
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Serum albumin level <3.5 g/dL
Number of subjects: 150
Study: 28057014

Group type: EXPERIMENTAL
Intervention: CART-EGFR therapy
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: CART133 treatment
Number of subjects: 1
Study: 28057609

Group type: EXPERIMENTAL
Intervention: IntelliCare apps with coach assistance (8 weeks of coaching including an initial phone call and 2 or more texts per week)
Number of subjects: 99
Study: 28057644

Group type: EXPERIMENTAL
Intervention: Topical cysteamine 0.55% eye drops
Number of subjects: 32
Study: 28057654

Group type: EXPERIMENTAL
Intervention: Hypoxia exposure (3-hour exposure simulating altitude of 4000 m.a.s.l.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 0
Study: 28057664

Group type: EXPERIMENTAL
Intervention: Pertuzumab-based treatment
Number of subjects: 1443
Study: 28059466

Group type: EXPERIMENTAL
Intervention: Clinic weights
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Researcher-measured weights
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Growth curve modeling
Number of subjects: 571
Study: 28060205

Group type: EXPERIMENTAL
Intervention: Emotional self-awareness treatment (8 lessons with psychoeducational information and skill-building exercises)
Number of subjects: 17
Study: 28060358

Group type: EXPERIMENTAL
Intervention: First-generation retinal implant Alpha IMS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Next-generation retinal implant (under assessment in a second clinical trial)
Number of subjects: 0
Study: 28060600

Group type: EXPERIMENTAL
Intervention: Hypercaloric refeeding with low-GI diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hypercaloric refeeding with high-GI diet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overfeeding (OF)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hypercaloric refeeding (RF)
Number of subjects: 15
Study: 28060738

Group type: EXPERIMENTAL
Intervention: High level of ctDNA
Number of subjects: 34
Study: 28061430

Group type: EXPERIMENTAL
Intervention: Insulin detemir (once-daily)
Number of subjects: 17374

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 17374
Study: 28061905

Group type: EXPERIMENTAL
Intervention: M. perstans infection assessment
Number of subjects: 2247

Group type: EXPERIMENTAL
Intervention: Culicoides species assessment using CDC light traps and Human Landing Catch (HLC) method
Number of subjects: 2247

Group type: EXPERIMENTAL
Intervention: Correlation assessment between Culicoides spp. and M. perstans prevalence
Number of subjects: 2247
Study: 28062312

Group type: EXPERIMENTAL
Intervention: Chronic pancreatitis (CP) group
Number of subjects: 1301

Group type: COMPARATOR
Intervention: Biliary diseases (BD) group
Number of subjects: 1301
Study: 28062389

Group type: EXPERIMENTAL
Intervention: Keep It Up! (KIU!) intervention, which includes modules with videos, animation, games, and interactive exercises.
Number of subjects: 901

Group type: COMPARATOR
Intervention: Control condition reflecting readily available HIV information on websites.
Number of subjects: 901
Study: 28062631

Group type: EXPERIMENTAL
Intervention: Algorithms that included cardiac troponin (cTn) and glucose
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Algorithms incorporating glucose with cTn
Number of subjects: 1137

Group type: EXPERIMENTAL
Intervention: Algorithms for MI/cardiovascular death
Number of subjects: 1137
Study: 28062705

Group type: EXPERIMENTAL
Intervention: PAK4 allosteric modulators (PAMs) including KPT-7523, KPT-7189, KPT-8752, KPT-9307, and KPT-9274
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KPT-9274
Number of subjects: 0
Study: 28063459

Group type: EXPERIMENTAL
Intervention: Angiotensin enzyme converting inhibitors (86% of patients)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Beta-blockers (84% of patients)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: LV remodeling assessment (increase in end-diastolic volume (EDV) and/or ejection fraction (EF))
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Phase-contrast Cardiovascular Magnetic Resonance (CMR)
Number of subjects: 121
Study: 28063717

Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsions (LE)
Number of subjects: 45
Study: 28064152

Group type: EXPERIMENTAL
Intervention: Left atrial expansion index
Number of subjects: 733

Group type: COMPARATOR
Intervention: Lowest quartile of LA expansion index
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Renal function decline
Number of subjects: 733
Study: 28065165

Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy
Number of subjects: 19
Study: 28065396

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) at 0 to 200 μg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Inhaled corticosteroids (ICS) at 200 to 800 μg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) at 200 μg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) at 800 μg
Number of subjects: 121

Group type: COMPARATOR
Intervention: ICS free
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Higher dose ramps of ICS
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: All 3 dose ramps of ICS
Number of subjects: 121
Study: 28065408

Group type: EXPERIMENTAL
Intervention: Short luteal phase (≤11 days)
Number of subjects: 284
Study: 28065465

Group type: EXPERIMENTAL
Intervention: Gefitinib plus metformin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Gefitinib plus placebo
Number of subjects: 200
Study: 28065678

Group type: EXPERIMENTAL
Intervention: PADQOL-16 instrument
Number of subjects: 0
Study: 28065708

Group type: EXPERIMENTAL
Intervention: Second-generation BAT system
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: First-generation BAT system (active therapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: First-generation BAT system (sham control)
Number of subjects: 30
Study: 28065734

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass in adults
Number of subjects: 100
Study: 28065736

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 58
Study: 28066274

Group type: EXPERIMENTAL
Intervention: 10 sessions standardized pain-focused EMDR in addition to treatment-as-usual (TAU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) alone
Number of subjects: 40
Study: 28067703

Group type: EXPERIMENTAL
Intervention: General anesthesia with halothane; 65% received regional or local anesthesia (caudal block in 79.23% or nerve block in 20.77%); average duration of surgery 33 ± 17.47 minutes.
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Ambulatory surgery program
Number of subjects: 103
Study: 28067743

Group type: EXPERIMENTAL
Intervention: Robotic-assisted sacrocolpopexy (RSC)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Uterosacral ligament suspension (USLS)
Number of subjects: 78
Study: 28068212

Group type: EXPERIMENTAL
Intervention: HZ/su vaccine (2 doses, 2 months apart)
Number of subjects: 96
Study: 28068460

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 12 weeks
Number of subjects: 808
Study: 28068465

Group type: EXPERIMENTAL
Intervention: Bipolar disorder with psychotropic exposure (BD+)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Bipolar disorder without psychotropic treatment (BD-)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control group (nonexposed infants)
Number of subjects: 197
Study: 28068480

Group type: EXPERIMENTAL
Intervention: NeoCart implant
Number of subjects: 29